These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15718695)

  • 1. Predictive biosimulation and virtual patients in pharmaceutical R and D.
    Bangs A
    Stud Health Technol Inform; 2005; 111():37-42. PubMed ID: 15718695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of clinical efficacy.
    Michelson S; Sehgal A; Friedrich C
    Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reengineering the pharmaceutical industry by crash-testing molecules.
    Swaan PW; Ekins S
    Drug Discov Today; 2005 Sep; 10(17):1191-200. PubMed ID: 16182212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimulation software is changing research.
    Ho RL; Bartsell LT
    Biotechnol Annu Rev; 2004; 10():297-302. PubMed ID: 15504712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connecting the dots: role of standardization and technology sharing in biological simulation.
    Ghosh S; Matsuoka Y; Kitano H
    Drug Discov Today; 2010 Dec; 15(23-24):1024-31. PubMed ID: 20934535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
    Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative risk modelling for new pharmaceutical compounds.
    Tang Z; Taylor MJ; Lisboa P; Dyas M
    Drug Discov Today; 2005 Nov; 10(22):1520-6. PubMed ID: 16257374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helping science to succeed: improving processes in R&D.
    Sewing A; Winchester T; Carnell P; Hampton D; Keighley W
    Drug Discov Today; 2008 Mar; 13(5-6):227-33. PubMed ID: 18342798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.
    Peppercorn J; Blood E; Winer E; Partridge A
    Cancer; 2007 Apr; 109(7):1239-46. PubMed ID: 17326054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in knowledge management for pharmaceutical research and development.
    Torr-Brown S
    Curr Opin Drug Discov Devel; 2005 May; 8(3):316-22. PubMed ID: 15892246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a paradigm of drug innovation: an evaluation algorithm.
    Caprino L; Russo P
    Drug Discov Today; 2006 Nov; 11(21-22):999-1006. PubMed ID: 17055409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public-private partnership: from there to here.
    Croft SL
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
    Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
    J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomics and drug discovery.
    Van Osta P; Ver Donck K; Bols L; Geysen J
    Cytometry A; 2006 Mar; 69(3):117-8. PubMed ID: 16496374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brazil: An emerging partner in drug R&D.
    Rodrigues DG
    IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.